{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:43:05Z","timestamp":1794994985090,"version":"4.9.1"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DNA damage responses (DDR) occur during oncogenesis and therapeutic responses to DNA damaging cytotoxic drugs. Thus, a real-time method to image DNA damage in vivo would be useful to diagnose cancer and monitor its treatment. Toward this end, we have developed fluorophore- and radioisotope-labeled immunoconjugates to target a DDR signaling protein, phosphorylated histone H2A variant H2AX (\u03b3H2AX), which forms foci at sites of DNA double-strand breaks. Anti-\u03b3H2AX antibodies were modified by the addition of diethylenetriaminepentaacetic acid (DTPA) to allow 111In labeling or the fluorophore Cy3. The cell-penetrating peptide Tat (GRKKRRQRRRPPQGYG) was also added to the immunoconjugate to aid nuclear translocation. In irradiated breast cancer cells, confocal microscopy confirmed the expected colocalization of anti-\u03b3H2AX-Tat with \u03b3H2AX foci. In comparison with nonspecific antibody conjugates, 111In-anti-\u03b3H2AX-Tat was retained longer in cells. Anti-\u03b3H2AX-Tat probes were also used to track in vivo DNA damage, using a mouse xenograft model of human breast cancer. After local X-ray irradiation or bleomycin treatment, the anti-\u03b3H2AX-Tat probes produced fluorescent and single photon emission computed tomography signals in the tumors that were proportionate to the delivered radiation dose and the amount of \u03b3H2AX present. Taken together, our findings establish the use of radioimmunoconjugates that target \u03b3H2AX as a noninvasive imaging method to monitor DNA damage, with many potential applications in preclinical and clinical settings. Cancer Res; 71(13); 4539\u201349. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-4587","type":"journal-article","created":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T21:57:13Z","timestamp":1305669433000},"page":"4539-4549","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Imaging DNA Damage\n                    <i>In Vivo<\/i>\n                    Using \u03b3H2AX-Targeted Immunoconjugates"],"prefix":"10.1158","volume":"71","author":[{"given":"Bart","family":"Cornelissen","sequence":"first","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Kersemans","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Darbar","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Shah","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sleeth","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hill","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Vallis","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: CR-UK\/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,6,30]]},"reference":[{"key":"2022061702554963100_bib1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"key":"2022061702554963100_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nature03485","article-title":"Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions","volume":"434","author":"Gorgoulis","year":"2005","journal-title":"Nature"},{"key":"2022061702554963100_bib3","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.4161\/cc.5.24.3569","article-title":"GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence","volume":"5","author":"Sedelnikova","year":"2006","journal-title":"Cell Cycle"},{"key":"2022061702554963100_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2022061702554963100_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2004.07.009","article-title":"DNA double strand break quantification in skin biopsies","volume":"72","author":"Qvarnstrom","year":"2004","journal-title":"Radiother Oncol"},{"key":"2022061702554963100_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0091-679X(04)75014-1","article-title":"Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation","volume":"75","author":"Olive","year":"2004","journal-title":"Methods Cell Biol"},{"key":"2022061702554963100_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nprot.2006.17","article-title":"Radiolabeling of HYNIC-Annexin V with technetium-99m for in vivo imaging of apoptosis","volume":"1","author":"Blankenberg","year":"2006","journal-title":"Nat Protoc"},{"key":"2022061702554963100_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nm.1938","article-title":"Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes","volume":"15","author":"Edgington","year":"2009","journal-title":"Nat Med"},{"key":"2022061702554963100_bib9","first-page":"2035","article-title":"Past, present, and future of Annexin A5: from protein discovery to clinical applications","volume":"46","author":"Boersma","year":"2005","journal-title":"J Nucl Med"},{"key":"2022061702554963100_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-10-4","article-title":"Residual gammaH2AX foci as an indication of lethal DNA lesions","volume":"10","author":"Banath","year":"2010","journal-title":"BMC Cancer"},{"key":"2022061702554963100_bib11","first-page":"4347","article-title":"Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks","volume":"63","author":"Banath","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702554963100_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","article-title":"GammaH2AX and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2022061702554963100_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00412-009-0234-4","article-title":"H2AX: functional roles and potential applications","volume":"118","author":"Dickey","year":"2009","journal-title":"Chromosoma"},{"key":"2022061702554963100_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heitz","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2022061702554963100_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cbr.2007.0430","article-title":"Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications","volume":"23","author":"Costantini","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"2022061702554963100_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00259-006-0189-0","article-title":"123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1\/Cip-1)","volume":"34","author":"Hu","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022061702554963100_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.nucmedbio.2009.05.003","article-title":"In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy","volume":"36","author":"Cornelissen","year":"2009","journal-title":"Nucl Med Biol"},{"key":"2022061702554963100_bib18","first-page":"7272","article-title":"Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator","volume":"50","author":"Hnatowich","year":"1990","journal-title":"Cancer Res"},{"key":"2022061702554963100_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nucmedbio.2006.10.008","article-title":"Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells","volume":"34","author":"Cornelissen","year":"2007","journal-title":"Nucl Med Biol"},{"key":"2022061702554963100_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/rpd\/ncl429","article-title":"Experimental techniques for studying bystander effects in vitro by high and low-LET ionising radiation","volume":"122","author":"Hill","year":"2006","journal-title":"Radiat Prot Dosimetry"},{"key":"2022061702554963100_bib21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2967\/jnumed.108.051805","article-title":"Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF","volume":"49","author":"Cai","year":"2008","journal-title":"J Nucl Med"},{"key":"2022061702554963100_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"key":"2022061702554963100_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4161\/cbt.9.3.10751","article-title":"DNA damage signaling is activated during cancer progression in human colorectal carcinoma","volume":"9","author":"Oka","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"2022061702554963100_bib24","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.humpath.2008.03.007","article-title":"Expression of gamma-H2AX in melanocytic lesions","volume":"39","author":"Wasco","year":"2008","journal-title":"Hum Pathol"},{"key":"2022061702554963100_bib25","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/1078-0432.CCR-07-5147","article-title":"DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing","volume":"14","author":"Rube","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702554963100_bib26","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1158\/1078-0432.CCR-08-3114","article-title":"gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation","volume":"15","author":"Banuelos","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061702554963100_bib27","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-09-0434","article-title":"Bringing DNA repair in tumors into focus","volume":"15","author":"Lord","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061702554963100_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0076-6879(05)09014-2","article-title":"Techniques for gamma-H2AX detection","volume":"409","author":"Nakamura","year":"2006","journal-title":"Methods Enzymol"},{"key":"2022061702554963100_bib29","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"2022061702554963100_bib30","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"2022061702554963100_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ygyno.2010.11.037","article-title":"Expression of gamma-H2AX in endometrial carcinomas: an immunohistochemical study with p53","volume":"121","author":"Brunner","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2022061702554963100_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF00251616","article-title":"Stability of 111In-bleomycin in vivo-properties compared with 57Co-bleomycin","volume":"8","author":"Hou","year":"1983","journal-title":"Eur J Nucl Med"},{"key":"2022061702554963100_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","article-title":"Passive and active drug targeting: drug delivery to tumors as an example","author":"Torchilin","year":"2010","journal-title":"Handb Exp Pharmacol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/13\/4539\/2651593\/4539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/13\/4539\/2651593\/4539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:40:45Z","timestamp":1655451645000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/13\/4539\/567613\/Imaging-DNA-Damage-In-Vivo-Using-H2AX-Targeted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,30]]},"references-count":33,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2011,6,30]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-4587","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22387656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387653.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387650.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387656.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387653","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6501975.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501975","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,30]]}}}